Drugs / heme arginate
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00682370 | Oct 2007 → Jul 2008 | — | Daniel Doberer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00483587 | Jul 2007 → Feb 2010 | acute myocardial infarction | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 1/2 | NCT00004789 | Jul 1993 → ? | porphyria | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02314780 | Mar 2015 → Jun 2017 | myocardial ischemia | Martin Andreas, M.D. | Completed | Mixed |
| Phase 2 | NCT01461512 | Jan 2009 → Aug 2011 | ischemic disease | MWolzt | Unknown | No outcome recorded |
| Phase 2 | NCT00004396 | Sep 1997 → ? | porphyria | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00856817 | Mar 2009 → ? | atherosclerotic cardiovascular disease | Radboud University Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Comparator or background therapy5 trials | ||||||
| Phase 1 | NCT00004397 Background | Jan 1998 → May 2000 | porphyria | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 1 | NCT00004398 Background | Jan 1998 → May 2000 | porphyria | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2 | NCT02142699 Comparator | Oct 2014 → Oct 2015 | acute kidney injury | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT03646344 Comparator | Mar 2019 → Mar 2020 | transplant rejection | University of Edinburgh | Terminated | No outcome recorded |
| Phase 3 | NCT01430156 Comparator | Jan 2012 → Jun 2013 | ischemic disease | University of Edinburgh | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | heme arginate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856817 ↗ |
| Known as | Haem arginate | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297285 ↗ |
| Known as | Normosang | “This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2.” NCT01430156 ↗ |
| Action | Activate | “treatment with heme arginate results in better clinical outcome by inducing the heme oxygenase-1 (HO-1) pathway.” NCT00483587 ↗ |
| Modality | Small molecule | — CHEMBL4297285 ↗ |
| Route | Intravenous | “Heme arginate is administered as a single intravenous infusion.” NCT00004396 ↗ |
| Target | HMOX1 | “Heme arginate is a strong inducer of HO-1 as shown in several animal experimental studies.” NCT00682370 ↗ |